OccuLogix, Inc., an ophthalmic therapeutic company, provides treatments for eye diseases. Its treatments primarily include age-related macular degeneration and glaucoma. The company develops RHEO System, which consists of the OctoNova Pump and a disposable treatment set, is designed to improve microcirculation in the eye by filtering high molecular weight proteins and other macromolecules from the patient’s plasma. It also provides the SOLX Glaucoma System for the treatment of glaucoma. OccuLogix operates in the United States, Canada, Europe, and Israel. The company was founded in 1996 and is headquartered in Mississauga, Canada.